UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 10-QSB/A

(X) QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934



FOR THE QUARTER ENDED FEBRUARY 28, 2003

ALLERGY IMMUNO TECHNOLOGIES, INC.

|Delaware                                                       | 95-3937129                          
|-------------------------------------------------------------- | ------------------------------------
|(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.)

|20462 Chartwell Center Drive, Cornelius, NC 28031                                           
|--------------------------------------------------------------------------------------------
|(Address of principal executive offices)                                                    
|                                                                                            
|Registrant's telephone number including area code:(704) 896-0202                            
|                                                                                            
|Securities registered under Section 12(b) of the Exchange Act: 
NONE                        
|Securities registered under Section 12(g) of the Exchange Act:
COMMON STOCK, PAR VALUE $.001

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

YES( ) NO (X)

Number of shares of the issuer's common stock, par value $.001, outstanding as of February 28, 2003: 17,978,948 shares.

Item 1.  FINANCIAL STATEMENTS

Allergy Immuno Technologies, Inc.Financial StatementsNine Month Period Ended February 28, 2003

Allergy Immuno Technologies, Inc.Financial StatementsNine and Three Month Periods Ended February 28, 2003, and 2002



Table Of Contents



|                                                                                                                 | Page
|---------------------------------------------------------------------------------------------------------------- | ----
|Balance Sheet (Unaudited) As of February 28, 2003                                                                | 1   
|Statements of Operations (Unaudited) For the Nine Month and Three Month Periods Ended February 28, 2003 and 2002 | 2   
|Statements of Shareholders' Deficit
    (Unaudited) For the Nine Month Period Ended February 28, 2003            | 3   
|Statements of Cash Flows (Unaudited) For the Nine Month Periods Ended February 28, 2003 and 2002                 | 4   
|Notes to Financial Statements                                                                                    | 5-6 
|Management's Discussion and Analysis of Financial Condition
    And Selected Financial Data                      | 7-9 

|                                                                |                                    |                             |                                             |  |                       |                       |   |                       |  |  | 1   
|--------------------------------------------------------------- | ---------------------------------- | --------------------------- | ------------------------------------------- |  | --------------------- | --------------------- | - | --------------------- |  |  | ----
|Allergy Immuno Technologies, Inc.                              
|                                                                |                                    |                             |                                             |  |                       |                       |   |                       |  |  |     
|Balance Sheet (Unaudited)                                      
|As of the Nine Month Period Ended february 28,                 
|                                                                |                                    |                             |                                             |  |                       |                       |   |                       |  |  |     
|                                                                |                                    |                             |                                             |  |                       |                       |   |                       |  |  |     
|                                                                |                                    |                             |                                             |  |                       |                       |   |                       |  |  | 2003
|                                                                |                                    |                             |                                             |  |                       |                       |   |                       |  |  |     
|Assets                                                          |                                    |                             |                                             |  |                       |                       |   |                       | 
|                                                                |                                    |                             |                                             |  |                       |                       |   |                       |  |  |     
|Current Assets                                                  |                                    |                             |                                             |  |                       |                      
|                                                                | Cash and Cash Equivalents          |                             |                                             |  | $                   -
|                                                                | Net Accounts Receivable            |                             |                                             |  |                       | -                    
|                                                                | Inventory                          |                             |                                             |  |                       |                       |   | -                    
|                                                                | Prepaid and Other Current Assets   |                             |                                             |  | -                    
|                                                                |                                    | Total Current Assets        |                                             |  |                       |                       | -
|                                                                |                                    |                             |                                             |  |                       |                       |   |                       |  |  |     
|Long-Term Assets                                                |                                    |                             |                                             |  |                      
|                                                                | Net Fixed Assets                   |                             |                                             |  |                       | -                    
|                                                                | Net Intangible Assets              |                             |                                             |  |                       | -                    
|                                                                |                                    | Long-Term Assets            |                                             |  |                       |                       | -
|                                                                |                                    |                             |                                             |  |                       |                       |   |                       |  |  |     
|                                                                |                                    |                             | Total Assets                                |  |                       |                       |   | $                   -
|                                                                |                                    |                             |                                             |  |                       |                       |   |                       |  |  |     
|                                                                |                                    |                             |                                             |  |                       |                       |   |                       |  |  |     
|Liabilities and Shareholders' Deficit                           |                                    |                             |                                             | 
|                                                                |                                    |                             |                                             |  |                       |                       |   |                       |  |  |     
|Current Liabilities                                             |                                    |                             |                                             |  |                      
|                                                                | Accounts Payable                   |                             |                                             |  |                       | $                   -
|                                                                | Accrued Liabilities - Compensation |                             |                                             |  | -                    
|                                                                | Accrued Liabilities - Other        |                             |                                             |  | 87,929               
|                                                                | Notes Payable - Current (Note 3)   |                             |                                             |  | 225,282              
|                                                                |                                    | Total Current Liabilities   |                                             |  |                       | 313,211              
|                                                                |                                    |                             |                                             |  |                       |                       |   |                       |  |  |     
|Shareholders' Deficit                                           |                                    |                             |                                             |  |                      
|                                                                | Common Stock (Note 4)              |                             |                                             |  |                       | 17,979               
|                                                                | Additional-Paid-In-Capital         |                             |                                             |  | 1,898,929            
|                                                                | Retained Earnings                  |                             |                                             |  |                       | (2,230,119)          
|                                                                |                                    | Total Shareholders' Deficit |                                             |  |                       | (313,211)            
|                                                                |                                    |                             |                                             |  |                       |                       |   |                       |  |  |     
|                                                                |                                    |                             | Total Liabilities and Shareholders' Deficit |  |                       | $                   -
|                                                                |                                    |                             |                                             |  |                       |                       |   |                       |  |  |     
|The accompanying notes are an integral part of these statements |                                   







|                                                                |                            |                          |                  |                             |            |                           |                           |                         |                                 |                           |                                 |                         |                           |                       | 2
|--------------------------------------------------------------- | -------------------------- | ------------------------ | ---------------- | --------------------------- | ---------- | ------------------------- | ------------------------- | ----------------------- | ------------------------------- | ------------------------- | ------------------------------- | ----------------------- | ------------------------- | --------------------- | -
|Allergy Immuno Technologies, Inc.                               |                            |                          |                  |                            
|                                                                |                            |                          |                  |                             |            |                           |                           |                         |                                 |                           |                                 |                         |                           |                       |  
|Statements of  Operations (Unaudited)                           |                            |                          |                  |                            
|                                                                |                            |                          |                  |                            
|                                                                |                            |                          |                  |                             |            |                           |                           |                         | Nine Months Ended 
February 28, |                           | Three Months Ended
February 28,
|                                                                |                            |                          |                  |                             |            |                           |                           |                         |                                
|All Discontinued Operations                                     |                            |                          | 2003             |                             | 2002       |                           | 2003                      |                         | 2002                           
|                                                                |                            |                          |                  |                             |            |                           |                           |                         |                                 |                           |                                 |                         |                           |                       |  
|Net Sales                                                       |                            |                          |                  |                             |            | $                       - |                           | $                41,453 |                                 | $                       - |                                 | $                12,682
|Cost of Sales                                                   |                            |                          |                  |                             | -          |                           | 57,638                    |                         | -                               |                           | 19,144                         
|                                                                | Gross Income (Loss)        |                          |                  | -                           |            | (16,185)                  |                           | -                       |                                 | (6,462)                  
|                                                                |                            |                          |                  |                             |            |                           |                           |                         |                                 |                           |                                 |                         |                           |                       |  
|Operating Expenses                                              |                            |                          |                  |                             |            |                           |                           |                         |                                
|                                                                | General and Administrative |                          |                  | 87,929                      |            | 49,923                    |                           | 37,574                  |                                 | 15,696                   
|                                                                |                            | Total Operating Expenses |                  | 87,929                      |            | 49,923                    |                           | 37,574                  |                                 | 15,696                   
|                                                                |                            |                          | Operating Loss   |                             |            | (87,929)                  | -                         | (66,108)                |                                 | (37,574)                  |                                 | (22,158)               
|                                                                |                            |                          |                  |                             |            |                           |                           |                         |                                 |                           |                                 |                         |                           |                       |  
|                                                                |                            |                          | Net Other Income |                             |            | -                         |                           | 26                      |                                 | -                         |                                 | 22                     
|                                                                |                            |                          |                  | Loss Before Income Taxes    |            | (87,929)                  |                           | (66,082)                |                                 | (37,574)                  |                                 | (22,136)               
|                                                                |                            |                          |                  |                             |            |                           |                           |                         |                                 |                           |                                 |                         |                           |                       |  
|                                                                |                            |                          |                  | Income Tax Expense (Note 6) |            | -                         |                           | 800                     |                                 | -                         |                                 | 800                    
|                                                                |                            |                          |                  |                             | Net Loss   |                           |                           | $            (87,929)   |                                 | $            (66,882)     |                                 | $            (37,574)   |                           | $            (22,936)
|                                                                |                            |                          |                  |                             |            |                           |                           |                         |                                 |                           |                                 |                         |                           |                       |  
|                                                                |                            |                          |                  |                             |            |                           |                           |                         |                                 |                           |                                 |                         |                           |                       |  
|Per Share Data (basic and diluted):                             |                            |                          |                  |                             |            |                           |                           |                        
|                                                                |                            |                          |                  |                             |            |                           |                           |                         |                                 |                           |                                 |                         |                           |                       |  
|Net Loss                                                        |                            |                          |                  |                             |            |                           | $                       - |                         | $                       -       |                           | $                       -       |                         | $                       -
|Weighted average number of common shares outstanding            | 17,978,948                 |                          | 17,170,390       |                             | 17,978,948 |                           | 17,170,390               
|                                                                |                            |                          |                  |                             |            |                           |                           |                         |                                 |                           |                                 |                         |                           |                       |  
|                                                                |                            |                          |                  |                             |            |                           |                           |                         |                                 |                           |                                 |                         |                           |                       |  
|The accompanying notes are an integral part of these statements |                            |                          |                  |                             |            |                          







|                                                                |            |           |             |                   |             |                    |            |                    |           |       | 3           
|--------------------------------------------------------------- | ---------- | --------- | ----------- | ----------------- | ----------- | ------------------ | ---------- | ------------------ | --------- | ----- | ------------
|Allergy Immuno Technologies, Inc.                              
|                                                                |            |           |             |                   |             |                    |            |                    |           |       |             
|Statements of Shareholders' Deficit (Unaudited)                
|For the Nine Month Period Ended February 28, 2003              
|                                                                |            |           |             |                   |             |                    |            |                    |           |       |             
|                                                                |            |           |             |                   |             |                    |            |                    |           |       |             
|                                                                |            |           |             |                   |             |                    |            |                    |           |       |             
|                                                                |            |           |             |                   |             |                    |            |                    |           |       |             
|                                                                |            |           |             |                   |             |                    |            |                    |           |       |             
|                                                                |            |           |             |                   |             | Common Stock       | Additional | Accumulated        |           | Total
|                                                                |            |           |             |                   |             |                    |            | Paid-In            | Income    |       | Shareholders
|                                                                |            |           |             |                   |             | Shares             | Amount     | Capital            | (Deficit) |       | (Deficit)   
|                                                                |            |           |             |                   |             |                    |            |                    |           |       |             
|May 31, 2002                                                    |            |           | 17,978,948  | $  17,979         | $ 1,898,929 | $     (2,142,190)  |            | $        (225,282)
|Net Loss                                                        |            |           |             |                   |             |                    | (87,929)   |                    | (87,929) 
|                                                                |            |           |             |                   |             |                    |            |                    |           |       |             
|February 28, 2003                                               | 17,978,948 | $  17,979 | $ 1,898,929 | $     (2,230,119) |             | $        (313,211)
|                                                                |            |           |             |                   |             |                    |            |                    |           |       |             
|                                                                |            |           |             |                   |             |                    |            |                    |           |       |             
|                                                                |            |           |             |                   |             |                    |            |                    |           |       |             
|The accompanying notes are an integral part of these statements |            |          







|                                                      |                                                                                                     |                                                                 |                                                           |                     |        |                         |                           |                      |                      |  | 4
|----------------------------------------------------- | --------------------------------------------------------------------------------------------------- | --------------------------------------------------------------- | --------------------------------------------------------- | ------------------- | ------ | ----------------------- | ------------------------- | -------------------- | -------------------- |  | -
|Allergy Immuno Technologies, Inc.                    
|                                                      |                                                                                                     |                                                                 |                                                           |                     |        |                         |                           |                      |                      |  |  
|Statement of Cash Flows (Unaudited)                  
|For the Nine Month Period Ended February 28,         
|                                                      |                                                                                                     |                                                                 |                                                           |                     |        |                         |                           |                      |                      |  |  
|                                                      |                                                                                                     |                                                                 |                                                           |                     |        |                         |                           |                      |                      |  |  
|All Discontinued Operations                           |                                                                                                     |                                                                 | 2003                                                      |                     | 2002  
|                                                      |                                                                                                     |                                                                 |                                                           |                     |        |                         |                           |                      |                      |  |  
|Cash Flows Provided by (Used in) Operating Activities |                                                                                                     |                                                                 |                                                          
|                                                      | Net Loss                                                                                            |                                                                 |                                                           |                     |        | $              (87,929) |                           | $           (66,882)
|                                                      | Adjustments to reconcile net (loss) 
to net provided by (used in) cash used in operating activities |                                                                 |                                                           |                    
|                                                      |                                                                                                     |                                                                 |                                                          
|                                                      |                                                                                                     | Depreciation and Amortization                                   |                                                           |                     | -      |                         | 955                      
|                                                      |                                                                                                     | (Increase) Decrease in Accounts Receivable                      |                                                           | -                   |        | 3,442                  
|                                                      |                                                                                                     | (Increase) Decrease in Inventory                                |                                                           | -                   |        | 1,169                  
|                                                      |                                                                                                     | (Increase) Decrease in Prepaid and Other Current Assets         | -                                                         |                     | 2,352 
|                                                      |                                                                                                     | Increase (Decrease) in Accounts Payable and Accrued Liabilities | 87,929                                                    |                     | 34,224
|                                                      |                                                                                                     |                                                                 | Net Cash Flows Provided by (Used in) Operating Activities | -                   |        | (24,740)               
|                                                      |                                                                                                     |                                                                 |                                                           |                     |        |                         |                           |                      |                      |  |  
|Cash Flows Provided by (Used in) Financing Activities |                                                                                                     |                                                                 |                                                          
|                                                      | Advances from affiliate                                                                             |                                                                 |                                                           | -                   |        | 16,190                 
|                                                      |                                                                                                     | Net Cash Flows Provided by (Used in) Investing Activities       | -                                                         |                     | 16,190
|                                                      |                                                                                                     |                                                                 |                                                           |                     |        |                         |                           |                      |                      |  |  
|                                                      |                                                                                                     |                                                                 | Net Cash Flows                                            |                     |        | -                       |                           | (8,550)             
|                                                      |                                                                                                     |                                                                 | Cash, Beginning of Period                                 |                     |        | -                       |                           | 9,455               
|                                                      |                                                                                                     |                                                                 |                                                           | Cash, End of Period |        |                         | $                       - |                      | $                905





> 5

Allergy Immuno Technologies, Inc.Notes To Financial Statements February 28, 2003



1. Summary Of Significant Accounting Policies

Reference is made to Note 1 of the Notes to Financial Statements contained in the
Company's Annual Report on form 10-KSB for the fiscal year ended May 31, 2002, for a summary of significant accounting policies utilized by the Company and new accounting pronouncements.2. Disclosures

The accompanying balance sheet at February 28, 2003, and the statements of operations, cash flows and
shareholders' deficit for the three month and nine month periods ended February 28, 2003 and 2002 are unaudited and have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission.  Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures included herein are adequate to make the information presented not misleading. In our opinion, the condensed consolidated financial statements include all adjustments (consisting only of normal recurring accruals) necessary to present fairly the financial position, results of operations and cash flows for each interim period shown.3. Limitation on Results of OperationsResults of operations for the interim periods covered by this Report may not necessarily be indicative of results of operations for the full fiscal year.4. Notes PayableAllergy Immuno Technologies, Inc. has an outstanding demand promissory note for services rendered and expenses advanced by the former parent company, Biomerica.  The note is for $225,282 and accrues interest at 7% compounded annually until payment on the note is made.  As no term is specified a schedule of payments is not available.  The note was sold on May 30, 2002 to LDM, Holdings Inc.

> 6

Allergy Immuno Technologies, Inc.Notes To Financial Statements November 30, 2002(Continued)

5.     Net Loss Per ShareThe FASB has issued Statement of Financial Accounting Standards No. 128 (SFAS 128), "Earnings Per Share."  SFAS 128 is primarily a disclosure standard which requires public companies to present basic earnings per share (EPS) and, if applicable, diluted earnings per share, instead of primary and fully diluted earnings per share.  Basic EPS is computed by dividing net income for the year by the weighted average number of shares of common stock outstanding during the year.  Diluted EPS is computed by dividing net (loss) income for the year by weighted average number of shares of common stock and common stock equivalents outstanding during the year.
The following table illustrates the required disclosure of the reconciliation of the numerators and denominators of the basic and diluted EPS computations.



|                                                                     |  | Income              |  | Shares        |  | Per Share   
|-------------------------------------------------------------------- |  | ------------------- |  | ------------- |  | ------------
|For the Nine Month Period Ended February 28, 2003                    |  | (Numerator)         |  | (Denominator) |  | Amount      
|                                                                     |  |                     |  |               |  |             
|Basic EPS                                                            |  |                     |  |               |  |             
|Loss available to common shareholders                                |  | $        (87,929)   |  | 17,978,948    |  | $          -
|                                                                     |  |                     |  |               |  |             
|Effect of Dilutive Securities                                        |  |                     |  |               |  |             
|Options                                                              |  | $                 - |  | -             |  | $          -
|                                                                     |  |                     |  |               |  |             
|Diluted EPS                                                          |  |                     |  |               |  |             
|Loss available to common shareholders plus 
     assumed conversions |  | $        (87,929)   |  | 17,978,948    |  | $          -



|                                                                     |  | Loss                |  | Shares        |  | Per Share   
|-------------------------------------------------------------------- |  | ------------------- |  | ------------- |  | ------------
|For the Nine Month Period Ended February 28, 2002                    |  | (Numerator)         |  | (Denominator) |  | Amount      
|                                                                     |  |                     |  |               |  |             
|Basic EPS                                                            |  |                     |  |               |  |             
|Loss available to common shareholders                                |  | $        (66,882)   |  | 17,170,390    |  | $          -
|                                                                     |  |                     |  |               |  |             
|Effect of Dilutive Securities                                        |  |                     |  |               |  |             
|Options                                                              |  | $                 - |  | -             |  | $          -
|                                                                     |  |                     |  |               |  |             
|Diluted EPS                                                          |  |                     |  |               |  |             
|Loss available to common shareholders plus 
     assumed conversions |  | $        (66,882)   |  | 17,170,390    |  | $          -

6.	Going Concern

> The accompanying financial statements have been prepared assuming the Company will continue as a going concern.  During the fiscal year ended May 31, 2002, the Company discontinued all operations and these conditions raise substantial doubt about the
> Company's ability to continue as a going concern.7. Subsequent Events
> 
> At the end of the reporting period, we owed our principal shareholder, LDM Holdings, Inc., the sum of $313,211. Of this sum, $225,282 is the principal amount on a note payable, and $87,929 is due to accrued liabilities. On March 28, 2003, our board voted to convert $275,637 of our total obligation to LDM Holdings into 13,781,859 shares of our common stock, a price of $0.02 per share.

Item 2a. DESCRIPTION OF BUSINESS

GENERAL

OUR OPERATIONS

Allergy Immuno Technologies, Inc. (the "Company,"
"Allergy," "we," or "our"), has historically
provided clinical testing services to physicians, laboratories and
pharmaceutical firms in specialized areas of allergy and immunology.

TERMINATION OF OUR FORMER OPERATIONS AND THE SALE OF OUR ASSETS TO
BIOMERICA; POTENTIAL CONSEQUENCES OF OUR FAILURE TO CONDUCT A FORMAL SHAREHOLDER
VOTE IN CONNECTION WITH THE SALE OF OUR ASSETS

By the end of February 2002, Allergy had liabilities of $357,972 and assets
of only $18,974. Allergy had always experienced operating losses, and it had
historically relied on borrowings from its parent, Biomerica, Inc., to maintain
operations. Allergy had made attempts to sell its clinical testing business
beginning in September 2000. From September 2000 through June 2001 Allergy
contacted third party laboratories that might be interested in buying Allergy's
clinical testing business. These efforts yielded one interested party who
ultimately decided that Allergy's operations were too small for their needs.

In late February 2002, Biomerica's management decided that it could no longer
afford to lend money to Allergy to fund Allergy's operations. Biomerica's
decision to cease lending money to Allergy significantly impacted Allergy's
ability to continue to operate. Allergy's board met on March 7, 2002 to discuss
the impact of Biomerica's decision to cease lending funds to Allergy.

Allergy's board reasoned that Allergy's losses were likely to continue, and
without borrowings from Biomerica, Allergy would no longer have enough capital
to operate. The board concluded that Allergy's clinical testing services be
terminated as of March 14, 2002.

Allergy's board met again on March 25. At the March 25, 2002 meeting two
alternatives for the future of Allergy were discussed. One alternative was to
seek investors or purchasers for Allergy. The other alternative was to transfer
some of the liabilities and all of the assets of Allergy to its parent,
Biomerica.

Ultimately, Allergy's management concluded that Allergy's liabilities and
assets should be transferred to its parent Biomerica. Allergy's management,
based upon its attempt to sell Allergy's clinical testing business in early
2001, determined that a sale of Allergy's assets to a third party would not
yield a buyer without unreasonable effort. On April 30, 2002, Allergy
transferred its assets and liabilities to its former parent company, Biomerica.
The asset and liability transfer transaction between Allergy and Biomerica was
memorialized in a General Assignment Agreement.

Allergy's financial condition immediately before the asset and liability
transfer to Biomerica was as follows: Allergy owed Biomerica loans totaling
$333,382; these loans had accrued over several years. Allergy also owed accounts
payable to third parties totaling $27,307.61. Allergy also had the following
assets: $803 in cash, prepaid expenses totaling $582.31, aged accounts
receivable totaling $5,104.71, inventory valued at $2,600.48, fixed assets such
as computers and testing equipment, four patents, and options to purchase 10,000
units of Hollister-Stier, LLC at an exercise price of $10 per unit.

In furtherance of Allergy's plan to transfer its assets and liabilities to
Biomerica, Biomerica and Allergy agreed to the following General Assignment
Agreement: First, Allergy agreed to transfer to Biomerica its cash, prepaid
expenses, accounts receivable, inventory, fixed assets, and patents, and also
issued 808,467 shares of Allergy common stock to Biomerica and in return
Biomerica agreed to assume Allergy's accounts payable. Second, Biomerica reduced
the amount of the loan owed by Allergy from $333,382 to $225,282 (a reduction of
$108,100), and in return Allergy transferred to Biomerica the Hollister-Stier
options.

At the time of the asset and liability transfer from Allergy to Biomerica,
Biomerica controlled 74.53% of Allergy's outstanding shares. Biomerica thus
exercised control over Allergy's board and its management because of its
shareholder majority. Furthermore, at the time of the asset transfer, Allergy
and Biomerica shared common management. Biomerica's seven directors were Allen
Barbieri, David Barrows, Carlos Beharie, Francis R. Cano, Zackary S. Irani,
Janet Moore, and Dr. Robert A. Orlando. Three of the seven directors (Mr. Irani,
Ms. Moore, and Dr. Orlando) were also directors of Allergy. Allergy's fourth
director at such time was Susan Irani, Mr. Irani's cousin, whom Allergy deemed
to be an affiliate of Biomerica. All of Allergy's directors were elected by
Biomerica through its majority voting control of Allergy.

Further, at such time, Mr. Irani served as the Chief Executive Officer and
Ms. Moore served as the Chief Financial Officer and Secretary of both Biomerica
and Allergy. The asset and liability transfer was negotiated and executed by
management common to Allergy and Biomerica and was approved by all of the
directors of both companies. Thus, the asset and liability transfer was a
transaction with a related party.

Allergy did not conduct a formal shareholder vote in connection with our
decision to sell our assets to Biomerica, and thus, we did not mail proxy or
information materials to shareholders. Allergy's board was advised by counsel
that since Biomerica controlled 74.53% of Allergy's outstanding shares, Allergy
did not have to conduct a formal shareholder vote in connection with the
decision to sell the Allergy assets to Biomerica since they were not vital to
the operation of the corporation. The majority shareholder, Biomerica, had
approved the transfer of the assets. Allergy's assets at the time were not
significant, and in fact Allergy's liabilities greatly exceeded its assets-the
remaining assets only totaled $9,090. Allergy's only significant asset (which
was actually valued on the books at $0) was an option to buy some shares in
Hollister-Stier, a privately held company. Biomerica agreed to take that option
as partial payment for the note payable that AIT owed to Biomerica and reduced
the note accordingly. The value of $108,100 was assigned to the option after
consulting with Hollister-Stier.

Following the asset and liability transfer from Allergy to Biomerica, we
learned that our failure to call a shareholder vote in connection with the asset
transfer may have violated a provision of Delaware's corporate law. Delaware's
General Corporation Law (GCL) requires that the disposition or sale of "all
or substantially all" of a corporation's assets can only be made following
a formal shareholder vote called upon 20 days' notice. However, Delaware's GCL
also contains an apparently conflicting provision: a statute that allows a
corporation's majority shareholder to act by a written resolution in lieu of a
shareholder vote. This conflict between the two statutes has never been resolved
or interpreted by any specific case law.

Thus, our failure to call a formal shareholder vote in connection with the
sale of our assets could have potential consequences. Potentially, a minority
shareholder could bring a legal action under Delaware state law against Allergy
to either rescind the liability and asset transfer agreement, or to seek damages
against Allergy. As of the date of this filing, no shareholder has filed such an
action against us, and no shareholder has contacted us announcing an intention
to bring an action.

Our present attorney has advised us that the likelihood of such an action is
remote for the following reasons:

* No shareholder has yet announced dissatisfaction with the transaction
although it was announced publicly in June of 2002. * The amount of assets that
were the subject of the transfer were small (and were transferred along with
substantial liabilities), and thus the compensation due to shareholders upon a
successful claim would be correspondingly small. * The inconsistency in Delaware
law would open up a potential defense to such a claim.

Our attorney has also advised that were such a claim to be brought, that the
potential liability would be small for the following reasons:

* The amount of assets that were the subject of the transfer were small (and
were transferred along with substantial liabilities), and thus the compensation
due to shareholders upon a successful claim would be correspondingly small. *
The assets that were the subject of the transfer yielded only unprofitable
operations since Allergy's inception, and thus the compensation due to
shareholders upon a successful claim would be correspondingly small.

Our attorney has also advised that our potential liability under such a claim
would be incapable of precise determination because the measure of damages under
such a claim would depend upon a subjective determination of the value of the
assets and liabilities, if any, that Allergy transferred to Biomerica.

We have discussed with our independent accountant for the period ended May
31, 2002 the potential liability we face from our failure to follow the
formalities outlined in Delaware law. Our auditors have concluded that we are
unlikely to face any liability from our failure, and in the event we do face
liability, that such a liability would be small, but incapable of precise
determination. Thus, our auditors have concluded that an amendment to our
financial statements is not warranted.

BIOMERICA'S SALE OF ITS INTEREST IN ALLERGY

Following the execution of the General Assignment Agreement, Allergy was left
without business operations and became a blank check company. Biomerica
thereafter sought to sell substantially all of its ownership in Allergy to a
group that would commence new operations for Allergy or would merge Allergy with
a company with operations.

Biomerica's attorney learned of Allergy's plans in March, 2002 through his
representation of Biomerica. The Attorney was contacted in April by
representatives of Omnics International Corporation inquiring if the Attorney
knew of a blank check company either available for sale or available for merger
with an operating company.

At the time of Omnics International's inquiry to Biomerica, through its
attorney, Omnics International manufactured an omni-directional wheel that has
application to wheelchairs, robotics, forklifts, and any other device requiring
or benefiting from increased mobility. Omnics International was seeking to
purchase a publicly trading blank check company for the purpose of merging
Omnics International's operations with the publicly trading blank check company.
The company resulting from this planned consolidation would ideally be publicly
traded, would contain Omnics' business operations, and would eventually bear the
name "Omnics".

Biomerica's attorney then made the introduction between Omnics and
Biomerica/Allergy in a conference call in April of 2002. Direct negotiations
between Allergy and Omnics followed. LDM Holdings was formed by Omnics
International's principals during negotiations with Allergy for the specific
purpose of purchasing the controlling interest in Allergy. Omnics
International's attorney advised the formation of a separate company, LDM
Holdings, to purchase the Allergy shares for two reasons: one, Omnics
International had debt that could not be determined immediately but was likely
substantial, and two, Omnics International's board could not determine promptly
whether Omnics International was in good standing in its state of incorporation.
Thus, Omnics International's counsel advised that a new corporation affiliated
with Omnics International be formed to purchase the Allergy shares; this
component of Omnics International's and LDM Holding's plan called for Omnics
International to transfer its omni-directional wheel technology and related
assets to LDM Holdings once Omnics International's debt and corporate status
were resolved. Thereafter, LDM Holdings would either merge with Allergy, or
would transfer the omni-directional wheel technology and related assets to
Allergy.

Biomerica's and LDM Holdings's negotiations continued. Biomerica and LDM
Holdings reached final terms as follows: On May 30, 2002, Biomerica, Inc., sold
the following property to LDM Holdings:

*13,350,000 shares its stock. The shares represented 74.25% of the
outstanding voting shares of Allergy on the day of the sale. *The promissory
note for $225,282. The effect of the sale of the note is that Allergy no longer
owes $225,282 to Biomerica, but now owes it to LDM Holdings.

In return, LDM Holdings paid Biomerica $212,500 in cash. At the conclusion of
this transaction LDM Holdings became the majority shareholder of Allergy.

RECENT CHANGE IN CONTROL

On May 30, 2002, the Company underwent a change in control. Immediately
before Biomerica sold its interest in Allergy to LDM Holdings, it was a 75.67%
shareholder in Allergy. Biomerica sold 74.25% of Allergy's outstanding shares to
LDM Holdings on May 30, leaving Biomerica with 1.42% of Allergy's outstanding
shares. Thus, following May 30 Biomerica no longer had a business relationship
with Allergy, and was no longer a majority shareholder in Allergy.

At the time of Biomerica's sale of its controlling interest in Allergy to LDM
Holdings, Allergy had the following four directors: Zackary Irani, Susan Irani,
Dr. Robert Orlando, and Janet Moore. All four of these directors were affiliated
with Biomerica. Dr. Robert Orlando issued a written letter of resignation on May
21, 2002, indicating that such resignation was to be effective immediately upon
the sale of Biomerica's controlling interest in Allergy. On June 6, 2002,
Allergy's board of directors took the following corporate actions by unanimous
written resolution:

*Dr. Robert Orlando's resignation was accepted by the remaining directors.
*Louis Marrero, Dean Martin, and John Peca were appointed to Allergy's board. *Zackary
Irani resigned from the board. *Susan Irani resigned from the board. *Janet
Moore resigned from the board.

Louis Marrero and Dean Martin were affiliated with Omincs International, and
John Peca was an attorney representing Omnics International.

Soon thereafter, on June 12, 2002, Allergy's board of directors took the
following corporate actions by unanimous written resolution:

*The current officers, Zackary Irani, CEO, and Janet Moore, CFO and secretary
were removed from office. *Louis Marrero was appointed as president. *Dean
Martin was appointed as treasurer. *John Peca was appointed as secretary.

Soon thereafter, on June 18, 2002, Allergy's board of directors took the
following corporate actions by unanimous written resolution:

*The membership of the board of directors was increased from 3 persons to 5
persons. *C. Edward Poteat was appointed to the board. *Phillip S. Hoffman was
appointed to the board.

WHY ALLERGY'S CONSOLIDATION WITH OMNICS INTERNATIONAL FAILED

As discussed above, the Company had originally planned, following the change
in control, to either (i) ultimately acquire the omni-directional wheel
technology then owned by Omnics International Corporation, or (ii) ultimately
acquire the Omnics International Corporation outright. The purpose of either
plan was to bring the exploitation and development of the omni- directional
wheel technology and its operations under Allergy.

Following LDM Holdings' purchase of the Allergy shares, two of Allergy's new
directors, Mr. Dean Martin and Mr. Lou Marrero, Allergy's attorney, Omnics'
Attorneys, and Allergy's accountants set down to begin the work of preparing the
merger between Omnics/LDM and Allergy. Upon close examination of Omnics
International, the attorneys and accountants discovered the following problems
with Omnics International:

*Omnics International did not conduct proper periodic annual shareholder and
director meetings, and would require substantial expense and effort to correct.
*Omnics International did not maintain an appropriate minute book, and would
require substantial expense and effort to correct. *Omnics International's
financial records were not adequately maintained, and would require substantial
expense and effort to correct. *Omnics International had substantial debt.

Thus, Allergy's accountant, Allergy's attorney, and Omnics' attorneys advised
that a consolidation between Allergy and Omnics International could occur only
after tremendous expense and delay. Allergy's management, in August of 2002,
abandoned plans to pursue the consolidation with Omnics International.

Thus, Allergy remained without business operations. Management thereafter
determined that the company's business plan would be to locate and merge with a
suitable operating company.

Item 2b. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

THE FOLLOWING DISCUSSION OF THE FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF THE COMPANY SHOULD BE READ IN CONJUNCTION WITH THE
FINANCIAL STATEMENTS AND NOTES THERETO INCLUDED ELSEWHERE IN THIS REPORT.

THIS DISCUSSION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES. THE COMPANY'S ACTUAL RESULTS MAY DIFFER MATERIALLY FROM THOSE ANTICIPATED IN THESE FORWARD-LOOKING STATEMENTS AS A RESULT OF CERTAIN FACTORS, INCLUDING, BUT NOT LIMITED TO, COMPETITION AND OVERALL MACRO- ECONOMIC CONDITIONS.General

The Company formerly generated revenue by providing clinical testing services to doctors, laboratories and pharmaceutical firms in specialized areas of allergy and immunology determinations. However, in March of 2002, Allergy's board resolved to terminate Allergy's operations.Plan of OperationAllergy has had no business operation since March of 2002. Allergy's present operational plan is to find a suitable operating company with which Allergy can merge, or to purchase the assets of a business with operations. Our President, Dean Martin, devotes an average of 15 hours per week to this effort, and is presently our sole employee, except for outside accountants and an outside attorney. Mr. Martin is not paid a salary for his efforts. We do not plan any product or service research and development in the pursuit of our plan. Similarly, we do not expect to purchase any plant or significant equipment. We do not expect any significant changes in the number of our employees.

Our only expenses of operation are general and administrative expenses, which are almost solely comprised of auditor fees and lawyer fees. We expect that we will expend $70,000 in fiscal 2003 on general and administrative expenses. Our cash requirements are presently satisfied by loans from our principal shareholder. Our principal shareholder intends to satisfy our cash requirements in this manner until August 30, at which time we may need to raise additional funds to pursue our plan of seeking a merger partner.Results of Operations (Operations Are Discontinued)NINE MONTHS ENDED FEBRUARY 28, 2003, COMPARED TO NINE MONTHS ENDED FEBRUARY 28, 2002

Revenues for the nine months ended February 28, 2003 were $0 as compared to $41,453 in the prior nine month period. The Company's decision to phase out its operations contributed solely to this 100% decrease in revenue over the prior period. Cost of sales was reduced from $57,638 to $0 as compared to the previous period. Again, our discontinuation of operations contributed solely to the elimination of cost of sales.

General and administrative expenses increased from $49,923 for the nine months ended February 28, 2002 to $87,929 for the comparable period in 2003, a 76% increase. Substantially all of the 76 percent increase can be attributed to our change of auditors in August of 2002. The change in auditors caused us to incur duplicate charges. The company had no research and development expenses in either period.Liquidity and Capital ResourcesAs of February 28, 2003, the Company had cash of $0 compared to $905 for the previous nine month period.
The Company's March 2002 decision to cease Company operations has and will significantly impact the Company's liquidity in the following ways:

> *The Company has reduced its administrative and operating expenses.
> *The Company has eliminated expenses related to its cost of sales.
> *The Company will continue to have reduced administrative and operating expenses.
> *The Company no longer has a source of revenue, and its sales will be $0 until it develops operations or finds a suitable operating company with which it can merge.
> *The Company is presently operating at a loss, and will continue to operate at a loss until it develops operations or finds a suitable operating company with which it can merge.
> *Management believes that losses will continue during fiscal 2003. As discussed above under the heading "Plan of Operation," our cash requirements are presently satisfied by loans from our principal shareholder. Our principal shareholder intends to satisfy our cash requirements in this manner until August 30, at which time we may need to raise additional funds to pursue our plan of seeking a merger partner.

Going ConcernThe accompanying financial statements have been prepared assuming the Company will continue as a going concern. We have no operations, and thus no source of revenue. We continue to incur operating expenses. We had substantial working capital and shareholders' deficits at May 31, 2002. These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

There can be no assurances that the Company will be able to successfully implement its plans, including generating profitable operations, generating positive cash flows from operations and obtaining additional debt and equity capital to meet present and future working capital demands.Research and DevelopmentDuring fiscal 2002 the Company did not spend any funds on research and development. The Company does not expect to engage in further research and development with respect to its former operations.ManufacturingAllergy does not currently perform any manufacturing.Item 3. LEGAL PROCEEDINGS

We are not a party to any legal proceedings.

Item 4. CHANGES IN SECURITIES AND USE OF PROCEEDS

The rights of security holders have not been materially modified during the reporting period.Item 5. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERSNo matters have been submitted to security holders during the reporting period.Item 6. EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

(a) Evaluation of Disclosure Controls and Procedures. Regulations under the Securities Exchange Act of 1934 require public companies to maintain "disclosure controls and procedures," which are defined to mean a company's controls and other procedures that are designed to ensure that information required to be disclosed in the reports that it files or submits under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in the Commission's rules and forms. Our chief executive and financial officer, based on his evaluation of the effectiveness of our disclosure controls and procedures within 90 days before the filing date of this report, concluded that our disclosure controls and procedures were effective for this purpose.

(b) Changes in Internal Controls. There were no significant changes in our internal controls or, to our knowledge, in other factors that could significantly affect our internal controls subsequent to the evaluation date referred to above.Item 7. EXHIBITS AND REPORTS ON FORM 8-Ka. Reports on Form 8-K.

> We filed no reports on form 8-K during the reporting period.

b. Exhibits:

> Exhibit 99.1. Certification of Chief Executive Officer
>   pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



Dated: May 12, 2003



ALLERGY IMMUNO TECHNOLOGIES, INC.

Registrant

By/s/ Larry Ball____________________________
Larry Ball,
President & CEO



CERTIFICATION

I, Larry Ball, certify that:

1. I have reviewed this quarterly report on Form 10-QSB/A of Allergy Immuno
Technologies, Inc.;

2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report.

4. I am responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the
registrant and I have:

a) designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the
period in which this quarterly report is being prepared;

b) evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this
quarterly report (the "Evaluation Date"); and

c) presented in this quarterly report our conclusions about the effectiveness
of the disclosure controls and procedures based on our evaluation as of the
Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based on
our most recent evaluation, to the registrant's auditors and the audit committee
of registrant's board of directors (or persons performing the equivalent
function):

a) all significant deficiencies in the design or operation of internal
controls which could adversely affect the registrant's ability to record,
process, summarize and report financial data and have identified for the
registrant's auditors any material weaknesses in internal controls; and

b) any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls; and

6. The registrant's other certifying officers and I have indicated in this
quarterly report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.

Date: May 12, 2003

By/s/ Larry Ball____________________________
Larry Ball,
President & CEO

CERTIFICATION

I, Emmett Ball, certify that:

1. I have reviewed this quarterly report on Form 10-QSB/A of Allergy Immuno
Technologies, Inc.;

2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report.

4. I am responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the
registrant and I have:

a) designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the
period in which this quarterly report is being prepared;

b) evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this
quarterly report (the "Evaluation Date"); and

c) presented in this quarterly report our conclusions about the effectiveness
of the disclosure controls and procedures based on our evaluation as of the
Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based on
our most recent evaluation, to the registrant's auditors and the audit committee
of registrant's board of directors (or persons performing the equivalent
function):

a) all significant deficiencies in the design or operation of internal
controls which could adversely affect the registrant's ability to record,
process, summarize and report financial data and have identified for the
registrant's auditors any material weaknesses in internal controls; and

b) any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls; and

6. The registrant's other certifying officers and I have indicated in this
quarterly report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.

Date: May 12, 2003

By: /s/ Emmett Ball
____________________________ 
Emmett Ball 
Chief Financial Officer

============================================================================

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, 
AS ADOPTED PURSUANT TO SECTION 906 OF THE 
SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Allergy Immuno Technologies,
Inc.(the "Company") on Form 10-Q for the period ended February 28,
2002, as filed with the Securities Exchange Commission on date hereof (the
"Report"), I, Larry Ball, the Chief Executive Officer of the Company,
certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the
best of my knowledge:

1. the Report fully complies with the requirements of Section 13(a) or 15(d)
of the Securities Exchange Act of 1934; and

2. the information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the Company.

Date: May 12, 2003

By/s/ Larry Ball____________________________
Larry Ball,
President & CEO

============================================================================

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, 
AS ADOPTED PURSUANT TO SECTION 906 OF THE 
SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Allergy Immuno Technologies,
Inc.(the "Company") on Form 10-Q for the period ended February 28,
2002, as filed with the Securities Exchange Commission on date hereof (the
"Report"), I, Emmett Ball, the Chief Financial Officer of the
Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
that, to the best of my knowledge:

1. the Report fully complies with the requirements of Section 13(a) or 15(d)
of the Securities Exchange Act of 1934; and

2. the information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the Company.

Date: May 12, 2003

By: /s/ Emmett Ball
____________________________ 
Emmett Ball 
Chief Financial Officer